No Money Down Real Estate Investing Course
Learn How To Buy Income Properties Without Risk, Good
Credit, Money Or Tenants!

Click here for more information
Welcome, Unregistered.
User Name
Forum Links
Site Navigation
Real Estate Resources
Go Back   Real Estate Investing > Real Estate General > Yahoo Investing Group
Thread Tools Search this Thread Display Modes
Old 09-28-2005, 09:33 AM
Posts: n/a


Recent SEC filings for key employee retention rights seems to
indicate an AVN merger.

The stock could soar but will shareholders keep AVN's subsidiary
Xenerex and AVN's anthrax antibody? It appears to be preparation for
a merger or maybe even a buyout. Alot of questions can be raised
but you can bet if there is a buyout, it better be in the high double
digits or shareholders will go after them as AVN has a Phase 3 drug
almost ready to go with remarkable results thus far and an anthrax
antibody created.

Either way, at less than $10 per share now, AVN looks like the best
buy around. Lazard just issued a BUY on AVN. This is very

for more info on AVN go to &
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~
AVANIR PHARMACEUTICALS filed this from their recent 8-K

Item 1.01. Entry into a Material Definitive Agreement.
On September 17, 2004, Avanir Pharmaceuticals (the "Company") entered
into Retention Agreements with eight key employees (the "Employees").
The form of Retention Agreement (the "Agreement") and a list of the
Employees is attached hereto as Exhibit 99.1. The Agreement provides
certain severance benefits to each respective Employee if his or her
employment is terminated following a "change of control" (as defined)
of the Company. These severance benefits will be paid only if: (i)
the change of control occurs prior to September 30, 2005, (ii) the
termination of employment occurs within 12 months following the
change of control, and (iii) the termination was without "cause" or
was a "resignation for good reason" (as such terms are defined). If
these conditions are met for a given Employee, he or she will receive
severance payments equal to twelve months of base salary, plus an
amount equal to the aggregate bonus payment(s) received by such
Employee in the Company's preceding fiscal year. Additionally, he or
she will have the ability to extend the exercise period of
outstanding stock option awards, such that they will remain
exercisable for 12 months from the date of termination.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~

After careful review, I am convinced that the technology employed by
AVN's subsidiary is distinctively superior than that employed by
their two biggest competitors of ABGX and PDLI. There are a few
smaller companies as well that can't even begin to compare. I believe
that AVN is completely undervalued and their Xenerex subsidiary alone
will be worth more than ABGX, PDLI and all the lessor companies
combined. Other than that, AVN itself has one of the most impressive
drug development pipelines with a potential blockbuster in Phase 3
and demonstrating undisputably impressive results. Given a bit more
time, AVN will hit a grand slam if all falls into place. If anyone
hasn't already done so, do check out the data on AVN's anthrax
antibody antidote. It will make you think about the potential of AVN
in fighting cancer and infectious diseases in the future. AVN is a
very solid company and completely undervalued.

Reply With Quote

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

All times are GMT -8. The time now is 11:59 PM.

Powered by: vBulletin Version 3.0.8
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
Search Engine Friendly URLs by vBSEO 2.4.0
Copyright 2001 - 2006, Buy Income Properties, Inc. All Rights Reserved. Privacy Policy in Observance.